TG Therapeutics Inc (TGTX.OQ)
TGTX.OQ on NASDAQ Stock Exchange Capital Market
5.50USD
15 Oct 2018
5.50USD
15 Oct 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$5.50
$5.50
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
345,563
345,563
52-wk High
$17.30
$17.30
52-wk Low
$4.95
$4.95
About
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered... (more)
Overall
| Beta: | 1.34 |
| Market Cap(Mil.): | $846.68 |
| Shares Outstanding(Mil.): | 68.84 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| TGTX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 85.91 | 32.75 |
| EPS (TTM): | -1.95 | -- | -- |
| ROI: | -129.83 | 1.70 | 14.60 |
| ROE: | -133.51 | 3.17 | 16.33 |
BRIEF-TG Therapeutics Reports Qtrly Loss Per Share Of $0.59
* TG THERAPEUTICS, INC. PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $133.95 | +0.08 |
| Novartis AG (NOVN.S) | CHF82.94 | +0.48 |
| Roche Holding Ltd. (ROG.S) | CHF237.30 | +2.05 |
| Roche Holding Ltd. (RO.S) | CHF238.40 | +1.80 |
| Merck & Co., Inc. (MRK.N) | $69.46 | -0.35 |
| Bayer AG (BAYGn.DE) | €77.68 | -0.39 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €75.70 | +0.41 |
| Abbott Laboratories (ABT.N) | $68.70 | -0.63 |
| Alexion Pharmaceuticals, Inc. (ALXN.OQ) | $121.49 | -- |
Estimates